SNDX analyst estimates
Syndax Pharmaceuticals (SNDX) analyst ratings, the average price target and its range, and every firm's latest call.
SNDX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 29, 2026 | Jefferies | Jefferies Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX) | $35.00 |
| Aug 21, 2026 | UBS | Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline | $33.00 |
| Aug 5, 2026 | H.C. Wainwright | Syndax price target lowered to $38 from $40 at H.C. Wainwright | $38.00 |
| Jun 12, 2026 | Guggenheim | Syndax price target lowered to $31 from $34 at Guggenheim | $31.00 |
| Jun 3, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX) | $40.00 |
| May 4, 2026 | Stifel Nicolaus | Syndax price target raised to $46 from $45 at Stifel | $46.00 |
| May 1, 2026 | Barclays | Syndax price target raised to $37 from $35 at Barclays | $37.00 |
| Feb 27, 2026 | Stifel Nicolaus | Syndax Pharmaceuticals (SNDX) PT Raised to $45 at Stifel | $45.00 |
| Nov 24, 2025 | Barclays | Syndax price target raised to $35 from $22 at Barclays | $35.00 |
| Nov 4, 2025 | Barclays | Syndax price target raised to $22 from $19 at Barclays | $22.00 |
| Nov 4, 2025 | UBS | Syndax price target raised to $38 from $35 at UBS | $38.00 |
| Sep 10, 2025 | Stifel Nicolaus | Syndax resumed with a Buy at Stifel | $44.00 |
| Jul 15, 2025 | UBS | Syndax price target lowered to $35 from $37 at UBS | $35.00 |
| Jul 10, 2025 | Goldman Sachs | Syndax initiated with a Buy at Goldman Sachs | $18.00 |
| Nov 13, 2024 | Scotiabank | Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank | $18.00 |
- 8 firms rate SNDX: 8 buy, 0 hold, 0 sell.
- The average price target is $34.25 from 4 analysts, from $31.00 to $38.00.
Updated 2026-11-03 00:02 UTC